Oppenheimer Maintains Outperform on Definium Therapeutics, Raises Price Target to $60
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Jay Olson maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $40 to $60.
Oppenheimer analyst Jay Olson maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $40 to $60.